Rationale and Design of EMPOWER, a Pragmatic Randomized Trial of Automated Hovering in Patients With Congestive Heart Failure

被引:10
|
作者
Mehta, Shivan J. [1 ,2 ,3 ]
Volpp, Kevin G. [1 ,2 ,3 ]
Asch, David A. [1 ,2 ,3 ]
Goldberg, Lee R. [1 ,2 ]
Russell, Louise B. [1 ,2 ]
Norton, Laurie A. [1 ,2 ]
Iannotte, Lauren G. [1 ,2 ]
Troxel, Andrea B. [4 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Dept Hlth Policy & Med Eth, Philadelphia, PA 19104 USA
[3] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA
[4] NYU, Sch Med, Dept Populat Hlth, Div Biostat, New York, NY USA
来源
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES | 2019年 / 12卷 / 04期
关键词
disease management; health care cost; heart failure; morbidity; mortality; HEALTH; HOSPITALIZATION; MANAGEMENT; ADHERENCE; OUTCOMES; RISK; MORTALITY; PATTERNS; SURVIVAL; MODEL;
D O I
10.1161/CIRCOUTCOMES.118.005126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Congestive heart failure is a major cause of morbidity, mortality, and cost. Disease management programs have shown promise but lack firm evidence of effectiveness and scalability. We describe the motivation, design, and planned analyses of EMPOWER (Electronic Monitoring of Patients Offers Ways to Enhance Recovery), a randomized clinical trial of an innovative intervention incorporating behavioral economic principles with remote monitoring technology embedded within a healthcare system. METHODS AND RESULTS: EMPOWER is an ongoing, pragmatic, randomized clinical trial comparing usual care to an automated hovering intervention that includes patient-level incentives for daily weight monitoring and diuretic adherence combined with automated feedback into the clinical care pathway, enabling real-time response to concerning clinical symptoms. Identification of eligible patients began in May 2016, and implementation of the intervention is feasible. Trial processes are embedded into existing clinical pathways. The primary outcome is time to readmission for any cause. Cost-effectiveness analyses are planned to evaluate the healthcare costs and health outcomes of the approach. CONCLUSIONS: The EMPOWER trial incorporates leading-edge approaches in human motivation, derived from behavioral economics, with contemporary technology to provide scale and exception handling at low cost. The trial is also implemented within the naturalized environment of a health system, as much as possible taking advantage of the existing journeys of patients and workflows of clinicians. A goal of this pragmatic design is to limit resource utilization and also to test an intervention that would need minimal modification to be translated from research into a new way of practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Rationale and design of a randomised trial of intravenous iron in patients with heart failure
    Kalra, Paul R.
    Cleland, John G. F.
    Petrie, Mark C.
    Ahmed, Fozia Z.
    Foley, Paul W. X.
    Kalra, Philip A.
    Lang, Ninian N.
    Lane, Rebecca E.
    Macdougall, Iain C.
    Pellicori, Pierpaolo
    Pope, Michael T. B.
    Robertson, Michele
    Squire, Iain B.
    Thomson, Elizabeth A.
    Ford, Ian
    HEART, 2022, 108 (24) : 1979 - 1985
  • [22] Use of Home Telemonitoring to Support Multidisciplinary Care of Heart Failure Patients in Finland: Randomized Controlled Trial
    Vuorinen, Anna-Leena
    Leppanen, Juha
    Kaijanranta, Hannu
    Kulju, Minna
    Helio, Tiina
    van Gils, Mark
    Lahteenmaki, Jaakko
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2014, 16 (12) : 178 - 189
  • [23] Rationale and Design of the ATHENA-HF Trial Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure
    Butler, Javed
    Hernandez, Adrian F.
    Anstrom, Kevin J.
    Kalogeropoulos, Andreas
    Redfield, Margaret M.
    Konstam, Marvin A.
    Tang, W. H. Wilson
    Felker, G. Michael
    Shah, Monica R.
    Braunwald, Eugene
    JACC-HEART FAILURE, 2016, 4 (09) : 726 - 735
  • [24] Heart failure in low- and middle-income countries: Background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF)
    Dokainish, Hisham
    Teo, Koon
    Zhu, Jun
    Roy, Ambuj
    Al-Habib, Khalid
    ElSayed, Ahmed
    Palileo, Lia
    Jaramillo, Patricio Lopez
    Karaye, Kamilu
    Yusoff, Khalid
    Orlandini, Andres
    Sliwa, Karen
    Mondo, Charles
    Lanas, Fernando
    Dorairaj, Prabhakar
    Huffman, Mark
    Badr, Amr
    Elmaghawry, Mohamed
    Damasceno, Albertino
    Belley-Cote, Emilie
    Harkness, Karen
    Grinvalds, Alex
    McKelvie, Robert
    Yusuf, Salim
    AMERICAN HEART JOURNAL, 2015, 170 (04) : 627 - +
  • [25] Clinical implication of sarcopenia in patients with acute decompensated heart failure: Design and rationale
    Bai, Bingqing
    Li, Dujuan
    Xu, Mingyu
    Liao, Yingxue
    Zhou, Haofeng
    Liu, Fengyao
    Li, Wen
    Ma, Huan
    ESC HEART FAILURE, 2025, 12 (01): : 640 - 648
  • [26] Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction
    Desai, Akshay S.
    Lewis, Eldrin F.
    Li, Rebecca
    Solomon, Scott D.
    Assmann, Susan F.
    Boineau, Robin
    Clausell, Nadine
    Diaz, Rafael
    Fleg, Jerome L.
    Gordeev, Ivan
    McKinlay, Sonja
    O'Meara, Eileen
    Shaburishvili, Tamaz
    Pitt, Bertram
    Pfeffer, Marc A.
    AMERICAN HEART JOURNAL, 2011, 162 (06) : 966 - U27
  • [27] Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
    Ambrosy, Andrew P.
    Malik, Umar, I
    Thomas, Rachel C.
    Parikh, Rishi, V
    Tan, Thida C.
    Goh, Choon H.
    Selby, Van N.
    Solomon, Matthew D.
    Avula, Harshith R.
    Fitzpatrick, Jesse K.
    Skarbinski, Jacek
    Philip, Sephy
    Granowitz, Craig
    Bhatt, Deepak L.
    Go, Alan S.
    AMERICAN HEART JOURNAL, 2021, 235 : 54 - 64
  • [28] ECG Al-Guided Screening for Low Ejection Fraction (EAGLE): Rationale and design of a pragmatic cluster randomized trial
    Yao, Xiaoxi
    McCoy, Rozalina G.
    Friedman, Paul A.
    Shah, Nilay D.
    Barry, Barbara A.
    Behnken, Emma M.
    Inselman, Jonathan W.
    Attia, Zachi, I
    Noseworthy, Peter A.
    AMERICAN HEART JOURNAL, 2020, 219 : 31 - 36
  • [29] The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction: An Analysis of the EVEREST Trial
    Mentz, Robert J.
    Schmidt, Philip H.
    Kwasny, Mary J.
    Ambrosy, Andrew P.
    O'Connor, Christopher M.
    Konstam, Marvin A.
    Zannad, Faiez
    Maggioni, Aldo P.
    Swedberg, Karl
    Gheorghiade, Mihai
    JOURNAL OF CARDIAC FAILURE, 2012, 18 (07) : 515 - 523
  • [30] Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
    Hundertmark, Moritz J.
    Agbaje, Olorunsola F.
    Coleman, Ruth
    George, Jyothis T.
    Grempler, Rolf
    Holman, Rury R.
    Lamlum, Hanan
    Lee, Jisoo
    Milton, Joanne E.
    Niessen, Heiko G.
    Rider, Oliver
    Rodgers, Christopher T.
    Valkovic, Ladislav
    Wicks, Eleanor
    Mahmod, Masliza
    Neubauer, Stefan
    ESC HEART FAILURE, 2021, 8 (04): : 2580 - 2590